PREGNANCY: No adequate or well-controlled studies have been conducted in pregnant women. Due to the lack of conclusive safety data, cabergoline should only be used in pregnancy if clearly needed. Cabergoline is classified in FDA pregnancy risk category B.
NURSING MOTHERS: Cabergoline should not be used in breastfeeding mothers because it interferes with the production of breast milk. It is not known whether cabergoline is excreted in human milk.
REFERENCE: FDA Prescribing Information.
Quick GuidePrescription Drug Abuse: Know The Warning Signs
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.